Delphi Diagnostics Inc. is a Texas-based company focused on advancing clinically valid tests for the prognosis and prediction of breast cancer treatment. Delphi Diagnostics, Inc. holds an exclusive license from The University of Texas MD Anderson Cancer Center in Houston, TX to commercialize the Endocrine Activity Index, a technology that was developed by the laboratory of Dr. W. Fraser Symmans. The Endocrine Activity Index (EAI) test measures endocrine activity in stage II-III, HR+HER2- breast cancer. Delphi’s vision is to make the EAI test available to breast cancer patients and open new pathways for personalized breast cancer treatment.
Company Details
- Employees
- 15
- Founded
- -
- Address
- Houston, Tx, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Houston, TX
Delphi Diagnostics Inc. Questions
Delphi Diagnostics Inc.'s website is https://www.delphi-diagnostics.com
Delphi Diagnostics Inc.'s LinkedIn profile is https://www.linkedin.com/company/delphi-diagnostics-inc
Delphi Diagnostics Inc. has
15 employees.
View email and phone details for 15
employees at Delphi Diagnostics Inc..
Delphi Diagnostics Inc.'s industry is
Biotechnology Research
Delphi Diagnostics Inc.'s top competitors are
Guardant Health,
Quest Diagnostics,
Digitaldx Ventures,
Thermo Fisher Scientific,
Vela Diagnostics,
Grail,
Bioscript Solutions,
Delfi Diagnostics,
Natera,
Optina Diagnostics.
Delphi Diagnostics Inc.'s categories are Biotechnology Research
Delphi Diagnostics Inc.'s founding year is 2016
